4 minuty

New EU Pharmacovigilance Requirements: What Regulation (EU) 2025/1466 Means for MAHs

On 22 July 2025, Regulation (EU) 2025/1466 was adopted, amending Implementing Regulation (EU) No. 520/2012. The update introduces a series of new pharmacovigilance (PV) requirements for EU-based Marketing Authorisation Holders (MAHs), with a clear focus on strengthening governance, transparency, and system interoperability.

These changes will have a direct impact on how PV systems are structured, audited, and maintained across the EU.

Implementation timeline

The regulation will be applied in two phases:

  • 12 August 2025 – selected provisions come into force, including updates related to EudraVigilance (EV) database usage
  • 12 February 2026 – full application of all requirements

This phased approach provides MAHs with a limited but critical window to assess gaps and implement necessary changes.

Strengthened oversight of subcontracting and third parties

One of the most significant updates concerns subcontracting arrangements.

MAHs are now required to ensure:

  • clear contractual obligations across the entire PV chain
  • explicit audit rights, including for downstream third parties
  • full visibility and control over outsourced PV activities

This reinforces accountability beyond direct vendors and extends responsibility across all involved entities.

Independent auditing and reinforced QMS oversight

The regulation places greater emphasis on governance integrity through:

  • independent auditing, ensuring objective assessment of PV systems
  • enhanced MAH responsibility for auditing their own Quality Management System (QMS)

These changes aim to improve consistency and reliability of PV processes while reducing compliance risks.

Enhanced signal management requirements

Signal detection and validation processes are also being strengthened.

MAHs must implement:

  • more robust signal validation procedures
  • clearer and more structured notification protocols

This reflects increasing regulatory expectations around proactive safety monitoring and timely communication.

PSMF simplification with focus on critical deviations

The updated regulation introduces a more targeted approach to the Pharmacovigilance System Master File (PSMF).

Instead of broad documentation, MAHs are now expected to:

  • focus on major and critical deviations
  • ensure that documentation remains relevant, accurate, and inspection-ready

This change is intended to improve usability while maintaining regulatory oversight.

Improved interoperability with EudraVigilance

Another key pillar of the regulation is enhanced interoperability with the EudraVigilance (EV) system.

This includes:

  • improved data exchange standards
  • alignment of systems for more efficient reporting and signal detection

Interoperability will be critical for ensuring data consistency across the EU PV ecosystem.

Expanded PSUR requirements

Periodic Safety Update Reports (PSURs) will now need to include:

  • updates on the implementation and effectiveness of Risk Minimisation Measures (RMMs)

This expands the role of PSURs beyond safety data aggregation to include real-world risk management evaluation.

Mandatory registration of PASS studies

Post-Authorisation Safety Studies (PASS) must now be registered in:

  • the EMA electronic post-authorisation study register

This requirement enhances transparency and allows regulators to better track ongoing safety studies.

DOI requirements for literature in ICSR reporting

A notable practical change concerns literature reporting.

Where available, MAHs are now expected to:

  • include Digital Object Identifiers (DOIs) when reporting literature-based ICSRs

This improves traceability, data quality, and consistency across safety reporting.

What this means for MAHs

Regulation (EU) 2025/1466 signals a clear shift toward:

  • increased accountability across PV systems
  • deeper control over outsourcing structures
  • stronger integration of data and processes

MAHs should begin gap analyses early and ensure alignment across governance, systems, and documentation before the full implementation deadline.

How MS Pharm supports compliance

At MS Pharm, we are actively preparing to support our partners in meeting these new requirements.

This includes:

  • ensuring structured literature monitoring aligned with new standards
  • providing DOI-enriched references for ICSR reporting
  • supporting PV system adaptation in line with evolving EU regulations

Conclusion

The updated EU pharmacovigilance framework introduces meaningful changes that will impact daily PV operations, from subcontracting and audits to signal management and reporting standards.

Early preparation and strategic alignment will be key to ensuring compliance and maintaining robust, inspection-ready PV systems.